FDA Approves Immunotherapy Keytruda for PD-L1+ TNBC

Moderators
Moderators Member Posts: 25,912
edited November 2020 in Immunotherapy - Before, During, and After

FDA Approves Immunotherapy Keytruda for PD-L1-Positive Triple-Negative Breast Cancer
November 13, 2020
On Nov. 13, 2020, the FDA approved the immunotherapy Keytruda in combination with chemotherapy to treat unresectable locally advanced or metastatic triple-negative, PD-L1-positive breast cancer. Read more...

· Share on FacebookShare on Twitter

Comments

  • Stillhavehope
    Stillhavehope Member Posts: 27
    edited November 2020

    is this only approved for a first line therapy or can it be used as a second or third line therapy

    · Share on FacebookShare on Twitter
  • moth
    moth Member Posts: 4,800
    edited November 2020

    I read the prescribing information & as far as I can tell it does not specify. The trial that they based the rapid approval was based on pts who had not had prior therapy but I don't see a statement about this in the prescribing info.

    I'd also note that the prescribing info also states it can be used for pts with any type of cancer which has high tumor mutation burden (TMB 10 or over) who have no other options. It's on p1 of the document, bottom of right hand column. https://www.accessdata.fda.gov/drugsatfda_docs/lab...


    · Share on FacebookShare on Twitter
  • Stillhavehope
    Stillhavehope Member Posts: 27
    edited November 2020

    Moth

    Thank you! I just like to gather information about new treatments and trials so I know what to bring to my MO. Abraxane and Tecentriq have been a great treatment for me so far

    · Share on FacebookShare on Twitter

Categories